France Adds Five Pegfilgrastims To Biosimilar Equivalence List
Five pegfilgrastim biosimilars have been added to a newly-created group in France’s list of similar biologics, with Neulasta as the reference brand. At the same time, the country’s ANSM medicines agency has also added further biosimilars to the list against other already-listed biologic brands, and has also created new generic groups for three molecules in its répertoire of generic equivalents.
You may also be interested in...
Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.
Pfizer’s Zirabev biosimilar bevacizumab has been added to France’s list of similar biologics alongside reference brand Avastin by local medicines agency ANSM.
French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.